Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -36.48 is 48600% below its 5-year average of -0.07, near the low end of its 5-year range (-36.48–9.64).
As of the fiscal period ended Tuesday, June 30, 2026. 264.26% below its 12-month average of -10.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -36.48.
DEBT TO EQUITY RATIO
-36.48
DEBT TO EQUITY RATIO AVG TTM
-10.01
DEBT TO EQUITY RATIO AVG 3Y
0.95
DEBT TO EQUITY RATIO AVG 5Y
-0.07
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-264.26%
CURRENT VS 3Y AVG
-3920.03%
CURRENT VS 5Y AVG
-48600.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 751 covered companies
CURRENT VS SECTOR MEDIAN
-33261.89%
vs the sector median at left
Fractyl Health, Inc.
Market Cap
$60.98M
Debt to Equity Ratio
-36.48
TTM Avg
-10.01
3Y Avg
0.95
5Y Avg
-0.07
Market Cap
$61.06M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.03
Market Cap
$61.28M
Debt to Equity Ratio
0.09
TTM Avg
0.33
3Y Avg
0.30
5Y Avg
0.26
Market Cap
$60.04M
Debt to Equity Ratio
N/A
TTM Avg
0.10
3Y Avg
0.06
5Y Avg
0.05
Market Cap
$59.60M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$63.16M
Debt to Equity Ratio
0.20
TTM Avg
0.18
3Y Avg
0.11
5Y Avg
0.08
Market Cap
$57.69M
Debt to Equity Ratio
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $60.98M | -36.48 | -10.01 | 0.95 | -0.07 |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.06M | 0.02 | 0.01 | 0.01 | 0.03 |
| Xilio Therapeutics, Inc. (XLO)vs › | $61.28M | 0.09 | 0.33 | 0.30 | 0.26 |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.04M | N/A | 0.10 | 0.06 | 0.05 |
| Adicet Bio, Inc. (ACET)vs › | $59.60M | 0.11 | 0.09 | 0.09 | 0.11 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.60M | 0.02 | 0.01 | 0.01 | 0.00 |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | 0.20 | 0.18 | 0.11 | 0.08 |
| MiNK Therapeutics, Inc. (INKT)vs › | $57.69M | N/A | 0.00 | 0.00 | 0.00 |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | 0.32 | 0.11 | 0.11 |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | 0.00 | 0.41 | 0.41 | 0.41 |
Debt/Equity
-36.48
Current Ratio
3.15
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -36.48 |
| 2026-03-31 | 2.84 |
| 2025-12-31 | 6.52 |
| 2025-09-30 | -19.57 |
| 2025-06-30 | -3.39 |
| 2025-03-31 | 9.64 |
| 2024-12-31 | 2.20 |
| 2024-09-30 | 1.25 |
| 2024-06-30 | 0.87 |
| 2024-03-31 | 0.72 |
| 2023-12-31 | -1.15 |
| 2023-09-30 | -0.18 |
| 2023-06-30 | -0.13 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | -1.22 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | -1.45 |
| 2021-09-30 | -1.54 |
| 2021-06-30 | -0.09 |
| 2021-03-31 | 0.20 |
| 2020-12-31 | 1.02 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
